Parasite polyamines as pharmaceutical targets

Sigrid Roberts, Buddy Ullman

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

There is an urgent need for the identification and validation of new therapeutic targets in protozoan parasites because currently available drugs are limited in number and usefulness, and no vaccines are available. The discovery that alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, is an efficacious treatment for African Sleeping Sickness caused by the protozoan parasite Trypanosoma brucei, has validated the polyamine pathway as a target in protozoan parasites. Polyamines are ubiquitous organic cations that play critical roles in key cellular processes such as growth, differentiation, and macromolecular biosynthesis. In recent years, remarkable progress has been made in the characterization of the polyamine pathway in a variety of protozoan parasites and this review will highlight surprising and unique features that could lead to new therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)3325-3341
Number of pages17
JournalCurrent Pharmaceutical Design
Volume23
Issue number23
DOIs
StatePublished - 2017

Keywords

  • Leishmania
  • Parasites
  • Plasmodium
  • Polyamines
  • Therapeutic strategies
  • Trypanosoma brucei
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Parasite polyamines as pharmaceutical targets'. Together they form a unique fingerprint.

Cite this